References of "Tancredi, Annalisa"
     in
Bookmark and Share    
See detailDe integratie van zorgkundigen in de thuisverpleging
Moons, P.; Gosset, Christiane ULg; Beckers, Jacqueline ULg et al

Report (2009)

Detailed reference viewed: 33 (2 ULg)
Full Text
Peer Reviewed
See detailThe combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors.
Allouche, Abdelkader; Nolens, Gregory ULg; Tancredi, Annalisa ULg et al

in Breast Cancer Research [=BCR] (2008), 10(1), 9

INTRODUCTION: Overexpression of the ERBB2 oncogene is observed in about 20% of human breast tumors and is the consequence of increased transcription rates frequently associated with gene amplification ... [more ▼]

INTRODUCTION: Overexpression of the ERBB2 oncogene is observed in about 20% of human breast tumors and is the consequence of increased transcription rates frequently associated with gene amplification. Several studies have shown a link between activator protein 2 (AP-2) transcription factors and ERBB2 gene expression in breast cancer cell lines. Moreover, the Yin Yang 1 (YY1) transcription factor has been shown to stimulate AP-2 transcriptional activity on the ERBB2 promoter in vitro. In this report, we examined the relationships between ERBB2, AP-2alpha, and YY1 both in breast cancer tissue specimens and in a mammary cancer cell line. METHODS: ERBB2, AP-2alpha, and YY1 protein levels were analyzed by immunohistochemistry in a panel of 55 primary breast tumors. ERBB2 gene amplification status was determined by fluorescent in situ hybridization. Correlations were evaluated by a chi2 test at a p value of less than 0.05. The functional role of AP-2alpha and YY1 on ERBB2 gene expression was analyzed by small interfering RNA (siRNA) transfection in the BT-474 mammary cancer cell line followed by real-time reverse transcription-polymerase chain reaction and Western blotting. RESULTS: We observed a statistically significant correlation between ERBB2 and AP-2alpha levels in the tumors (p < 0.01). Moreover, associations were found between ERBB2 protein level and the combined high expression of AP-2alpha and YY1 (p < 0.02) as well as between the expression of AP-2alpha and YY1 (p < 0.001). Furthermore, the levels of both AP-2alpha and YY1 proteins were inversely correlated to ERBB2 gene amplification status in the tumors (p < 0.01). Transfection of siRNAs targeting AP-2alpha and AP-2gamma mRNAs in the BT-474 breast cancer cell line repressed the expression of the endogenous ERBB2 gene at both the mRNA and protein levels. Moreover, the additional transfection of an siRNA directed against the YY1 transcript further reduced the ERBB2 protein level, suggesting that AP-2 and YY1 transcription factors cooperate to stimulate the transcription of the ERBB2 gene. CONCLUSION: This study highlights the role of both AP-2alpha and YY1 transcription factors in ERBB2 oncogene overexpression in breast tumors. Our results also suggest that high ERBB2 expression may result either from gene amplification or from increased transcription factor levels. [less ▲]

Detailed reference viewed: 134 (17 ULg)
Full Text
Peer Reviewed
See detailAnalysis of the discriminant ability of shorter versions of the French ADAM questionnaire
Tancredi, Annalisa ULg; Legros, Jean-Jacques ULg; Pire, G. et al

in Aging Male : The Official Journal of the International Society for the Study of the Aging Male (2007), 10(3), 159-164

Objective. To investigate whether shorter versions of the ADAM test, a screening questionnaire for andropause, provide better diagnostic value than the original tool. Methods. Five thousand and twenty ... [more ▼]

Objective. To investigate whether shorter versions of the ADAM test, a screening questionnaire for andropause, provide better diagnostic value than the original tool. Methods. Five thousand and twenty-eight volunteer men aged 50-70 years attending a screening campaign for andropause, provided a fasting blood sample and completed the French ADAM test. Logistic regression analysis identified items that best predict andropause defined as serum free testosterone level below 70 ng/l. ROC curves assessed the diagnostic value of modified versions of the ADAM test, obtained by elimination of the less relevant predictors of andropause. Results. Only four items of the ADAM questionnaire may account for the diagnosis of andropause. These items concerned loss of height, decrease in libido and in enjoyment of life and deterioration in work performance. Item 9 was borderline significant. The area under the ROC curve for the short versions varied slightly from 0.555 to 0.560. As expected, model 6 has a greater specificity (56.02%) than the original tool while the efficiency increased slightly (54.85%). Conclusion. The modified versions of the ADAM test do not provide better diagnostic value than the original tool. Conclusion. The modified versions of the ADAM test do not provide better diagnostic value than the original tool. [less ▲]

Detailed reference viewed: 42 (5 ULg)
Full Text
Peer Reviewed
See detailAssociation between osteoporosis and cardiovascular risk factors in postmenopausal women
Tancredi, Annalisa ULg; Polet, A. S.; Bosio-Le Goux, B. et al

in Osteoporosis International (2006, March), 17(Suppl.1), 84

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailComprehensive therapy in osteoporosis using a single drug: From ADFR to strontium ranelate
Manette, Christine ULg; Collette, Julien ULg; Sarlet, Nathalie ULg et al

in Current Medicinal Chemistry (2006), 13(13), 1585-1590

In vitro, strontium ranelate increases collagen and non-collagenic proteins synthesis by mature osteoblast enriched cells. The effects of strontium ranelate on bone formation were confirmed as the drug ... [more ▼]

In vitro, strontium ranelate increases collagen and non-collagenic proteins synthesis by mature osteoblast enriched cells. The effects of strontium ranelate on bone formation were confirmed as the drug enhanced preosteoblastic cell replication. In the isolated rat osteoclast, a preincubation of bone slices with strontium ranclate induced a dose-dependent inhibition of the bone resorbing activity of treated rat osteoclast. Strontium ranelate dose-dependently inhibited preosteoclast differentiation. In a phase 11 dose ranging trial Strontium ranclate (500 mg. 1000 mg, 2000 mg/day) or placebo were given to 353 postmenopausal women with prevalent vertebral osteoporosis. At the conclusion of this 2-year study. the annual increase in lumbar BMD of the group receiving 2000 mg of strontium ranclate was + 7.3%. a significant increase in bone alkaline phosphatase, over a 6-month period and a significant decrease in N-telopeptide crosslinks throughout the 2-year period were seen. During the second year of treatment, the dose of 2000 mg was associated with a 44% reduction in the number of patients experiencing a new vertebral deformity. The primary analysis of the SOTI study, evaluatine the effect of strontium ranelate 2000 mg on vertebral fracture rates, revealed a 41% reduction in the relative risk of patient experiencing a first new vertebral fracture with strontium ranelate throughout the 3-year study. The TROPOS study showed a significant reduction in the risk of experiencing a first non-vertebral fracture by 16% in the group treated with strontium ranclate throughout the 3-year study. A reduction in the risk of experiencing a hip fracture by 36% was also demonstrated in the patients at high risk of hip fracture (age >= 74 years and Femoral Neck T score <=-2.4 according to NHANES normative value). [less ▲]

Detailed reference viewed: 39 (2 ULg)
Full Text
Peer Reviewed
See detailNo major month to month variation in free testosterone levels in aging mates. Minor impact on the biological diagnosis of 'andropause'
Tancredi, Annalisa ULg; Reginster, Jean-Yves ULg; Luyckx, Françoise ULg et al

in Psychoneuroendocrinology (2005), 30(7), 638-646

BACKGROUND: The measurement of bioavailable testosterone (BT) or free testosterone (FT) levels is currently considered the gold standard for the diagnosis of androgen deficiency in elderly men. While the ... [more ▼]

BACKGROUND: The measurement of bioavailable testosterone (BT) or free testosterone (FT) levels is currently considered the gold standard for the diagnosis of androgen deficiency in elderly men. While the impact of age on circulating testosterone levels (total, bioavailable and free) has been strongly documented, the existence of seasonal variations in testosterone levels remains debated. OBJECTIVE: We investigated whether seasonal variations in serum calculated free testosterone (cFT) levels may translate into variations in the prevalence of low testosterone levels. Diagnosis was on the basis of biochemical determinations and was cross-checked with the prevalence of clinical signs and symptoms of 'andropause', as assessed by the Androgen Deficiency in Aging Males (ADAM) questionnaire. METHODS: The study recruited 5028 men aged 50 years and over from September 2000 to January 2003. Their serum FT levels were assessed and they completed the French ADAM test. Men were considered eugonadal when cFT was > or =70 ng/l. The ADAM test was scored as described originally. The prevalence of 'andropause', diagnosed by the two methods, was compared throughout the year, on a month by month basis. RESULTS: The percentage of subjects with cFT levels below 70 ng/l increased significantly with age (P<0.001). Serum cFT levels (mean [SD]) varied significantly with the month of sampling (P<0.0001), the highest (88.1 [30.2] ng/l) and lowest (76.9 [28.0] ng/l) mean values occurring in April and in October, respectively. Conversely, the prevalence of testosterone deficiency (cFT<70 ng/l) reached a peak in October (45.7%) and a nadir in April (29.7%). Although the prevalence of 'andropause', based on the ADAM questionnaire, increased significantly with age (P<0.0001), no influence of the month of the year was noticed. CONCLUSIONS: Our results confirm a progressive age-related decline in FT levels. The monthly variations in serum FT values, observed throughout the year, do not show a major seasonal rhythm in elderly community-dwelling males, since the magnitude of the variations (<15%) remains marginal. This slight variation may, however, have an impact on the number of elderly men diagnosed with Partial Androgen Deficiency in Aging Males (PADAM). [less ▲]

Detailed reference viewed: 35 (5 ULg)
Full Text
Peer Reviewed
See detailGlobal prevalence and skeletal implications of vitamin D inadequacy
Reginster, Jean-Yves ULg; Richy, Florent; Rabenda, Véronique ULg et al

in Annals of the Rheumatic Diseases (2005, June), 64(Suppl.III), 362

Detailed reference viewed: 15 (4 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis in daily clinical practice: prevalence of acute predictors in French postmenopausal women
Tancredi, Annalisa ULg; Bosio-Le goux, B.; Augendre-Ferrante, B. et al

in Osteoporosis International (2005, March), 16(Suppl.3), 108-109

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailCross-sectional assessment of risk factors associated with breast cancer among French postmenopausal women being prescribed an antiosteoporotic treatment
Tancredi, Annalisa ULg; Bosio-Le Goux, B.; Augendre-Ferrante, B. et al

in Osteoporosis International (2005, March), 16(Suppl.3), 108

Detailed reference viewed: 12 (4 ULg)
Full Text
Peer Reviewed
See detailManagement of osteoporosis after multi-risks assessment in French postmenopausal women
Tancredi, Annalisa ULg; Bosio-Le Goux, B.; Augendre-Ferrante, B. et al

in Osteoporosis International (2005, March), 16(Suppl.3), 108

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailPostmenopausal women initiating an antiosteoporotic treatment reported high prevalence of risk factors for cardiovascular diseases
Tancredi, Annalisa ULg; Bosio-Le Goux, B.; Augendre-Ferrante, B. et al

in Osteoporosis International (2005, March), 16(Suppl.3), 107

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailVitamin D inadequacy: global prevalence and skeletal implications
Reginster, Jean-Yves ULg; Richy, Florent; Rabenda, Véronique ULg et al

in Osteoporosis International (2005, March), 16(Suppl.3), 64

Detailed reference viewed: 10 (4 ULg)
Full Text
Peer Reviewed
See detailAnalysis of the discriminant ability of shorter versions of the French ADAM questionnaire
Tancredi, Annalisa ULg; Legros, Jean-Jacques ULg; Pire, George et al

in Osteoporosis International (2005, March), 16(Suppl.3), 39

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailInterest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers
Tancredi, Annalisa ULg; Reginster, Jean-Yves ULg; Schleich, FLorence ULg et al

in European Journal of Endocrinology (2004), 151(3), 355-360

Objective: To date, serum free testosterone measurement is considered to be the gold standard for the diagnosis of hypogonadism in elderly males but it is not available to all subjects suspected of a ... [more ▼]

Objective: To date, serum free testosterone measurement is considered to be the gold standard for the diagnosis of hypogonadism in elderly males but it is not available to all subjects suspected of a decrease in testicular function. Therefore, we evaluated whether the Androgen Deficiency in Aging Males (ADAM) questionnaire, in its original or in a modified 'quantitative' version (qADAM), could be used as a surrogate to biochemical determinations for the identification of hypogonadism in elderly males. Methods: 5028 men, aged 50-70 years, spontaneously consulting for the assessment of their gonadal function were studied. ADAM and qADAM, allocating a value of 1 point for any positive answer to each of the 10 questions of the ADAM test, were assessed for their ability to discriminate between males with free testosterone levels below or above 70 ng/l. Results: The sensitivity and specificity of the ADAM score were 81% and 21.6% respectively. The use of ADAM resulted in an appropriate classification of our population in normal or hypogonadal subjects in 44.5% of the cases. The area under the receiver operating characteristics (ROC) curve for the qADAM (0.529) revealed a highly marginal interest of this quantitative approach compared with the original scoring system. Conclusions: The ADAM test has a high sensitivity to identify aging males with low free testosterone levels. However, due to its lack of specificity, this test cannot be used as a surrogate to serum free testosterone testing for the identification of androgen deficiency in elderly, community-dwelling males. [less ▲]

Detailed reference viewed: 66 (4 ULg)